CoreCap Advisors’s BridgeBio Pharma BBIO Stock Holding History

CoreCap Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$65.8K	Hold	1,000	–	–	﹤0.01%	1273
2026 Q2	$74.5K	Hold	1,000	–	–	﹤0.01%	1237
2026 Q1	$74.3K	Hold	1,000	–	–	﹤0.01%	1147
2025 Q4	$76.5K	Hold	1,000	–	–	﹤0.01%	1138
2025 Q3	$51.9K	Hold	1,000	–	–	﹤0.01%	1314
2025 Q2	$43.2K	Buy	+1,000	New	+$36.4K	﹤0.01%	1314

Other funds holding BBIO

Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Oak Ridge Investments Chicago, Illinois $1.68B AUM 48.52% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

CoreCap Advisors's BBIO Position: Q3 2026 in Review

CoreCap Advisors held its BridgeBio Pharma (BBIO) position steady in Q3 2026 at 1,000 shares worth $65.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1273.

CoreCap Advisors first reported a position in BBIO in Q2 2025 and has held it in 6 quarters since. The position peaked at $76.5K in Q4 2025. 108 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

CoreCap Advisors held 1,000 shares of BridgeBio Pharma worth $65.8K as of Q3 2026.
CoreCap Advisors left its BridgeBio Pharma share count unchanged in Q3 2026.
BridgeBio Pharma made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #1273 holding.
CoreCap Advisors first reported a position in BridgeBio Pharma in Q2 2025 and has held it in 6 quarters since.
CoreCap Advisors's BridgeBio Pharma position peaked at $76.5K in Q4 2025.
108 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.